Background: The significance of lymph node involvement regarding the prognosis of primary duodenal adenocarcinoma remains controversial. This study aims to evaluate the prognostic accuracy of nodal metastasis using the seventh edition American Joint Committee on Cancer staging system in patients with primary duodenal adenocarcinoma. Methods: Between 1993 and 2010, 36 patients who had undergone surgical resection for primary duodenal adenocarcinoma at the Kaohsiung Veterans General Hospital were retrospectively reviewed. Results: The median disease-free survival for all patients was 19 months and the median overall survival was 21 months. Lymph node metastases were found in 26 (72%) of the patients, and 14 patients (39%) patients had in excess of three positive lymph nodes (N2). Patients with N2 disease had significantly reduced overall survival, as compared to patients with three or fewer positive lymph nodes (N1; p ¼ 0.036). In univariate analysis, factors including age >75 years, body weight loss, tumor size 4 cm, N2 disease and lymph node ratio >0.4 predicted shorter overall survival. Multivariate analysis demonstrated that N2 and lymph node ratio >0.4 are significant risk factors associated with overall survival ( p ¼ 0.026 and p ¼ 0.042 respectively). N2 is also the only independent predictive factor for disease-free survival ( p ¼ 0.023). Conclusion: Subdivision of metastatic lymph nodes into N1 and N2 improves predictive ability. The seventh edition American Joint Committee on Cancer staging system is applicable in the present study with regard to the prediction of the prognosis for primary duodenal adenocarcinoma.
Introduction
Primary duodenal adenocarcinoma is an uncommon tumor that accounts for less than 0.5% of all gastrointestinal malignancies. 1 Because of the rarity of this type of cancer, it has typically been reported together with jejunal and ileal tumors as a small bowel cancer, or in some cases grouped with periampullary malignancy, along with pancreatic, ampullary, and distal bile duct cancers. 2e4 Studies that focus only on duodenal adenocarcinoma are scarce. 5, 6 Correspondingly, many questions regarding disease pathogenesis, natural history, ideal medical management, and prognostic factors are still unanswered.
Until now, the significance of lymph node involvement regarding the prognosis of primary duodenal adenocarcinoma remains controversial. 7 However, some studies show a strong negative impact on survival in lymph node metastatic disease. 6, 8 The most common tool used to evaluate lymph node metastasis is the American Joint Committee on Cancer (AJCC) tumor-node-metatasis (TNM) staging system. Lymph node staging is divided into two groups: no regional lymph node metastasis (N0) and positive lymph node metastasis (N1) according to the sixth edition of the AJCC TNM classification system for small intestinal cancer published in 2002. 9 In 2010, the release of the seventh edition of AJCC classification included major modifications to the lymph node staging system. 10 The previous N1 group is further subdivided into new N1 (metastasis in 1e3 nodes) and N2 (metastasis in 4 or more nodes). As a result, the Stage III disease is subclassified into Stage IIIA (TxN1M0) and Stage IIIB (TxN2M0). However, the clinical correlation of this change has yet to be determined.
Apart from the involved lymph node, studies from other cancers have suggested that the total number of lymph nodes harvested is also an important indicator for prognosis because an insufficient number evaluated may not provide an accurate node staging.
11e13 Consequently, the idea of lymph node ratio (LNR) was introduced to eliminate the variation of dissection techniques by different surgeons and the number of lymph node harvested. This ratio is defined as the ratio of metastatic nodes to the total number of lymph node examined. Evidence presented in existing literature has demonstrated that the LNR is inversely related to survival in esophageal, gastric, and colon cancers. In this study, we aimed to clarify the prognostic impact of lymph node status, including AJCC node staging, the total number of lymph node examined, and the lymph node ratio in patients with primary duodenal adenocarcinoma treated with curative resection at a single medical center.
Methods
The medical records of all patients with primary duodenal adenocarcinoma who had undergone surgical resection at Kaohsiung Veterans General Hospital between 1993 and 2010 were reviewed retrospectively. All patients enrolled in this study had primary tumor located in the duodenum, and histologically proven adenocarcinoma. Tumors arising from ampulla of Vater, bile duct, and pancreas were excluded. Patients whose pathologic reports were not available were also excluded from the study.
A total of 36 patients met the inclusion criteria. Data for each patient were collected, including age at diagnosis, clinical presentation, type of surgery, postoperative course, and the use of adjuvant therapy. Anemia was defined as hemoglobin level <130 g/L in males, and <110 g/L in females. Pathologic specimens were reviewed for tumor location, size, tumor depth, histology, grade, surgical margin, pancreatic invasion, number of metastatic lymph node, and number of lymph nodes harvested. The lymph node ratio was calculated by dividing the number of metastatic lymph nodes by the total number of lymph nodes assessed. Patients were then subclassified into four groups based on LNR (LNR ¼ 0; 0 < LNR 0.2; 0.2 < LNR 0.4; 0.4 < LNR). The cutoff value for each group was determined by previous studies. 3, 17, 18 The seventh edition of AJCC classification for malignant neoplasms of the small intestine was used for staging.
Patients had regular postoperative follow-up examinations. Tumor recurrence was identified using various diagnostic tools such as sonography, computed tomography, magnetic resonance imaging, positron emission tomography scan, and whole body bone scan. Survival time and pattern of recurrence were recorded. Distant metastasis was suspected if the distal lesion was newly detected and did not appear in the preoperative survey. Biopsy might be considered if the lesion was not in any of the customary metastatic sites where duodenal adenocarcinoma is found (e.g. liver, peritoneum, lung). Informed consent was obtained from all patients before operation. The study complied with institutional review board protocols.
Statistical analyses were performed using SPSS 18.0 for Windows (SPSS, Inc., Chicago, IL, USA). Disease-free survival and overall survival were estimated by use of the Kaplan-Meier method and differences were compared by logrank test. Multivariate comparisons were conducted using the Cox proportional hazards model. Statistical significance was considered at p < 0.05.
Results

Patient characteristics
The clinicopathological data of enrolled patients were shown in Table 1 . Of the 36 patients reviewed, 24 (67%) were men and 12 (33%) were women. The median age at diagnosis was 66 years (range 35e88). Most of the tumors were located at the secondary portion of the duodenum (70%), followed by eight (22%) at the first portion, two (5%) at the third portion, and one case was found at the fourth portion. Also, 29 (80%) patients underwent classic pancreaticoduodenectomy (Whipple procedure) and two (6%) patients received pyloruspreserving pancreaticoduodenectomy (PPPD). Segmental duodenal resections were performed in five (14%) patients, four of whom had a tumor at the first portion, and one patient had a tumor at the fourth portion of the duodenum. All patient surgical margins were disease-free, except for one patient in the Whipple procedure group. Grossly, this patient's resection margins were free of tumor, but tumor cells were found microscopically in the distal pancreatic cut end. The AJCC nodal staging of this male patient was N2 and his LNR was 0.686 (11/16). He suffered from local recurrence 8 months later.
The median tumor size was 4 cm in diameter and the depth of tumor invasion was T4 in 72% of all patients. The median number of lymph nodes harvested was 16 (range 5e38), and 10 (28%) patients had no metastatic lymph nodes with an LNR of zero. Among the 26 patients who had positive lymph nodes, 12 patients had one to three positive lymph nodes (N1) and were classified as Stage IIIA. The other 14 patients had more than three positive lymph nodes (N2) and were classified as Stage IIIB. When categorized by LNR, there were 11 (30%) patients with LNR from 0 to 0.2, nine (25%) patients with LNR from 0.2 to 0.4 and six (17%) with LNR > 0.4. All of the eight (22%) patients who received adjuvant chemotherapy had node-positive disease.
Survival stratified by AJCC N classification and lymph node ratio
The median follow-up duration was 41 months for patients who survived and 17 months for patients who died. The 5-year overall survival rate of patients with N0, N1, and N2 disease (according to the current AJCC staging system) was 50%, 45% and 0%, respectively, ( p < 0.001; Fig. 1 ). Patients with N2 disease had a significantly shorter overall survival rate compared with patients with N0 and N1 disease ( p < 0.001 and p ¼ 0.036, respectively). However, no significant difference was detected in the overall survival between N0 and N1 disease ( p ¼ 0.238). Additionally, LNR is shown to be inversely associated with overall survival when categorized into four groups (LNR ¼ 0; 0 < LNR 0.2; 0.2 < LNR 0.4; 0.4 < LNR). Their 3-and 5-year overall survival rate were 90%, 31%, 29%, 0%, 50%, 31%, 0%, and 0%, ( p ¼ 0.011). However, there is no one distinctive LNR group that has a significant difference in overall survival in comparison with the other three groups (Fig. 2) .
Nineteen out of the 36 patients (53%) had recurrence of their cancer. The median time to recurrence after operation was 9 months (range 3e46). Local recurrence occurred in five (14%) cases and distant metastasis in six (17%) cases. Concurrent local and distant metastases were documented in the remaining eight (22%) cases. The liver was the most common site of distant metastasis followed by the peritoneum, lung, and bone. Palliative chemotherapy was given to three of the 19 recurrent patients (16%). Disease-free survival rates at 3 and 5 years for all 36 patients were 39% and 35%, respectively. Both the AJCC node classification and LNR were significantly associated with disease-free survival ( p ¼ 0.021 and 0.040, respectively; Fig. 3 and Fig. 4) . In subgroup analysis, N2 disease had shorter median diseasefree survival compared with N1 disease, but it did not reach statistical significance (8 months vs. 13 months, p ¼ 0.174). 
Prognostic factors associated with survival
Univariate analysis showed that patient factors including age >75 years ( p ¼ 0.020), body weight loss ( p ¼ 0.037), tumor size 4 cm ( p ¼ 0.041), AJCC N2 disease ( p < 0.001) (Fig. 5) and LNR > 0.4 ( p ¼ 0.014) were associated with decreased overall survival (Table 2) . Gender, anemia, tumor grade, T stage, tumor location, total lymph node examined, LNR > 2, pancreatic invasion, and the use of adjuvant chemotherapy had no significant influence on overall survival. Subsequent multivariate analysis using 2 different models were performed to avoid a confounding effect by putting the two lymph node factors (N2 disease, LNR > 0.4) together. The results demonstrated that N2 disease (hazard ratio ¼ 3.48, (Table 3) .
With respect to recurrence, anemia ( p ¼ 0.004), poor tumor grade ( p ¼ 0.017), tumor size 4 cm ( p ¼ 0.008), AJCC N2 disease ( p ¼ 0.010; Fig. 6 ), LNR > 0.4 ( p ¼ 0.026) and pancreatic invasion ( p ¼ 0.028) were found to have a significant negative impact on disease-free survival by univariate analysis (Table 4) . Similarly, 2 separate models were constructed using the Cox proportional hazards model to assess the influence of lymph node evaluation in disease-free survival. When multivariate analysis was employed, LNR > 0.4, along with anemia, tumor grade, and pancreatic invasion lost their prognostic significance. Only N2 disease remained as an independent factor predicting tumor recurrence (hazard ratio ¼ 3.36, p ¼ 0.023; Table 5 ).
Discussion
The principal goal of this study was to determine whether LN status, especially the new AJCC N-stage was associated with survival. Lymph node metastasis is a well-known prognostic factor for many gastrointestinal and periampullary malignancies.
19e22 When LN assessment occurs in the context of duodenal adenocarcinoma, however, there is some disagreement in this area. 7 Our data, in accordance with many other reports, have shown that patients with nodal metastases have diminished survival ( p < 0.001).
6e8,23e25 However, other studies have found no such relationship. 1, 26, 27 The incidence of lymph node metastasis in patients with duodenal adenocarcinoma has been reported to range from 22% to 76%, 6, 7, 28 and 72% of our patients had lymph node involvement. Given the relatively high percentage of nodal metastasis in our study, it is reasonable that our 5-year survival rate of 26% appeared to be lower in compared with other series (25e75%). 7 In this study, we found that the overall survival rate of patients with one to three positive lymph nodes (N1) did not differ significantly from that of patients without lymph node metastasis (N0; p ¼ 0.238). On the contrary, more than three lymph nodes involved (N2) was an independent predictor of overall and disease-free survival ( p ¼ 0.024 and p ¼ 0.023, respectively). Similar results had been found in patients with pancreatic carcinoma. 22,29e31 Zacharias et al 31 reported no statistically significant difference in survival between patients with a single metastatic node and patients with negative lymph nodes. However, they did find that patients with no more than one metastatic lymph node survived significantly longer than patients with two or more involved lymph nodes. They concluded that the presence of two or more positive lymph nodes was a major prognostic factor after resection of pancreatic carcinoma. These results also implied that a small number of positive lymph nodes might not affect clinical outcome, and that a subdivision according to the number of metastatic lymph nodes should be considered to provide better prognostic value.
Regarding small bowel adenocarcinoma, Overman et al. 32 demonstrated evident improvement in prognostic efficacy by stratifying patients with nodal metastasis into those patients with fewer than three positive lymph nodes and those with three or more positive lymph nodes (hazard ratio 1.44; 95% confidence interval 1.12e1.86). The 5-year disease-specific survival rates of the two subgroups were 58% and 37% respectively. The selected cutoff point for the number of positive lymph node in their study was slightly different compared with the seventh edition of AJCC N-staging (3 vs. >3 positive lymph nodes). Because in Overman's study, patients with tumors located in jejunum, ileum, and nonspecified locations were all included. When all circumstances were factored in, it could not be determined whether more than three positive lymph nodes is the cutoff value that has the best prognostic success in patients with duodenal adenocarcinoma. Based on our study, we clearly demonstrated that having more than three lymph node metastases (N2) is the most important factor to predict survival after curative resection. To our knowledge, this study is the first to validate the significant association between survival and N-staging of the seventh edition AJCC classification in patients with duodenal adenocarcinoma. There were five (14%) patients in our series who received segmental resection of the duodenum. Some investigators have proposed a pancreaticoduodenectomy procedure for all duodenal adenocarcinoma regardless of tumor location. 1 Others suggest duodenal segmentectomy as a less morbid choice for tumors located in the first, third, or fourth portions of the duodenum. 8, 25, 33 Inadequate surgical margins and lymph node clearance are the two major concerns for limited resection. 34 Kaklamanos et al 23 justified the use of segmental resection by showing a comparable number of lymph nodes removed, whether a pancreaticoduodenectomy or a duodenal segmentectomy was performed. A similar result was also found in our study ( p ¼ 0.436). Furthermore, no patient in our limited resection group had surgical margins involved by tumor. In all, our data support the use of the segmental resection procedure in selected patients with duodenal adenocarcinoma.
The total number of lymph nodes examined did not affect survival in our study (overall survival, p ¼ 0.296; disease-free survival, p ¼ 0.564) and in a small series reported by Struck et al. 35 Nevertheless, several investigators proposed that an inadequate number of lymph nodes removed may impair prognostic discrimination due to inaccurate assessment of lymph node metastasis, which might understage cancer patients. 3, 24, 32 The correlation between survival and the number of total lymph node evaluated have also been shown in esophageal, gastric, pancreatic, and colorectal cancers. 11e13,36 However, the exact number of lymph nodes that needed to be removed varied from study to study. For example, in pancreatic adenocarcinoma, the proposed number of lymph nodes that should be collected was reported to be 10, 12, or 15 nodes. 13, 17, 37 In a retrospective review of 522 patients with resected periampullary malignancies, Hurtuk et al 3 found that LNR is inversely associated with survival in pancreatic and ampullary cancer, but not in bile duct and duodenal cancer. In contrast, our results showed that LNR is predictive of disease-free survival and overall survival in patients with primary duodenal adenocarcinoma by categorizing patients into four groups using the same LNR cutoff values of 0, 0.2, and 0.4 ( p ¼ 0.011 and p ¼ 0.040 respectively). Besides, LNR > 0.4 was identified as an independent prognostic factor for overall survival ( p ¼ 0.012). Two studies of small bowel adenocarcinoma also reported significantly reduced survival rates in patients with LNR 0.5 and LNR 0.75, respectively. 4, 38 Theoretically, LNR is more discriminative than the number of positive lymph nodes (N-stage) in prognostic prediction because it incorporates the extent of lymphadenectomy. Furthermore, LNR may also eliminate the variation on specimen examination by different pathologists (e.g., the number of lymph nodes harvested). 17 Certain reports of cases of gastric and breast cancer have already demonstrated the prognostic efficacy of LNR and its superiority over current AJCC nodal staging categories. 15, 39 In the current study, more than three positive lymph nodes (N2 disease) exhibited prognostic value in both disease-free and overall survival rates, while LNR >0.4 failed to influence disease-free survival using multivariate analysis. Based on our findings, the number of metastatic lymph nodes was the more potent prognostic factor after resection of primary duodenal adenocarcinoma.
Another interesting finding of the present study was that smaller tumors (4 cm) were associated with a significantly poorer outcome than were larger ones (>4 cm) in univariate analysis (overall survival, p ¼ 0.040; disease-free survival, p ¼ 0.008). This seemingly counterintuitive result has also been observed by Hurtuk et al, 40 who found that larger tumors were less likely to behave aggressively. On the contrary, smaller tumors had a predilection to invade periduodenal fat or nearby structures. Furthermore, when they focused on tumors that invaded nearby structures, patients with larger tumors still showed better prognosis than those with smaller tumors. The authors explained those results by hypothesizing that there were differences in biological behaviors between duodenal adenocarcionomas and some tumors that tend to be less aggressive. Further study is required to clarify the biologic nature of this tumor. However, in the meantime, the authors suggested patients undergo aggressive surgical resection regardless of the tumor size. 40 In conclusion, our data validate the predictive power of nodal metastasis using N classification of the seventh edition AJCC staging system. More than three positive lymph nodes (N2 disease) is the most important prognostic factor in patients with primary duodenal adenocarcinoma after curative resection. The prognostic efficacy of LNR is promising and worthy of further larger scale research.
